Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
November 2012 Volume 4 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
November 2012 Volume 4 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Expression of connexin 32 and connexin 43 in acute myeloid leukemia and their roles in proliferation

  • Authors:
    • Sha Yi
    • Yan Chen
    • Lu Wen
    • Lijing Yang
    • Guohui Cui
  • View Affiliations / Copyright

    Affiliations: Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
  • Pages: 1003-1007
    |
    Published online on: August 29, 2012
       https://doi.org/10.3892/ol.2012.884
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Connexins (Cxs), a conserved family of transmembrane proteins, function in the organization of cell-cell communicatin via gap junctions in multicellular organisms. However, the role of Cxs in acute myeloid leukemia (AML) is poorly understood. In this study, we investigated the relationship between cell proliferation and expression of connexin 43 (Cx43) and connexin 32 (Cx32) mRNA and proteins in acute myeloid leukemia in vitro. Proliferation was observed using a growth curve and the rate of proliferation was detected by MTT assay in the acute myeloid leukemia cell lines OCI-AML3 and OCIM2. Cell cycle and cell proliferation index were assessed by flow cytometry analysis. The mRNA expression of the gap junction genes Cx43 and Cx32 was detected by RT-PCR. The expression of Cx43 and Cx32 proteins in the cell lines was analyzed by western blot analysis and immunofluorescence. The doubling time of OCI-AML3 and OCIM2 was 48 h and 36 h, respectively. In OCIM2, the percentage of cells in the S phase fraction was 59.47±9.6%, and the proliferation rate was 78.12±8.9%; however, in OCI-AML3, the percentage of cells in the S phase was 24.95±5.8%, and the proliferation rate was 35.21±6.7%. At the mRNA level, both cell lines expressed Cx43 and Cx32, and there was no significant difference in the expression of Cx43 and Cx32 mRNA in the two cell lines. At the protein level, there was a significant difference in the expression of Cx43, but not of Cx32. The proliferation ability of OCIM2 was higher than OCI-AML3, and OCIM2 exhibited higher Cx43 western blot and fluorescence intensities compared with OCI-AML3. The results suggest that a higher expression of Cx43 in AML cells may play a significant role in the proliferation ability.

Introduction

Acute myeloid leukemia (AML) is the most common type of hematological malignancy characterized by key properties, including blocked differentiation, enhanced self-renewal and increased proliferation. Although there have been great developments in the understanding and treatment of AML, the mortality of AML is still high. Due to the difficulties in tolerance of treatment, the molecular mechanisms of uncontrolled proliferation of AML have been a major research project all over the world.

Gap junctions consist of arrays of intercellular channels composed of two hemichannels or connexons, one of which is formed by six protein subunits, termed connexins (Cxs). Cxs are a conserved family of transmembrane proteins which regulate the passage of biological molecules and allow the exchange of signaling molecules smaller than 1 kDa between the cytoplasm of two neighboring cells, e.g. Ca2+, cyclic adenosine monophosphate (cAMP) and inositol triphosphate (IP3) (1–3). To date, at least 21 different human Cxs have been identified and they have been divided into two groups based on the primary amino acid sequence homology (3). It suggests that the dysregulation of Cx expression is related to uncontrolled proliferation, embryogenesis, tissue homeostasis and carcinogenesis (4). Recently, abnormal or defective gap junction communication in various solid tumors including liver, bladder, breast and prostate cancers was found (5), and accumulating research has also shown that restoring Cx gene expression and gap junction by gene therapy in Cx-deficient tumor cells could decrease tumor cell growth. However, despite much existing evidence, the exact contribution of the Cx channel family still remains controversial, as gap junction and cxs may furnish cell survival signals. The gap junction and cxs could exert their effect on promoting cancer cell proliferation (6,7). Each Cx shows tissue cell-specific expression, and Cx43 is the major component of hematopoietic tissue (8–11). Cx32 was also found to be important in bone marrow stromal cells (12,13). Until now, there have been few studies focusing on the expression of the gap junction genes in the AML cell lines, and little is known regarding the correlation between cell proliferation and Cxs. In this study, the AML cell lines OCI-AML3 and OCIM2 were employed to investigate the expression of Cx32 and Cx43 in AML and their role in proliferation.

Materials and methods

Cell culture

The OCI-AML3 and OCIM2 were kindly provided by M.D. Minden (Ontario Cancer Institute, Toronto, ON, Canada). OCI/AML3 (FAB M4) was established from a patient with AML, and OCIM2 (FAB M6) from a patient with erythroleukemia. The cells were grown in RPMI-1640 supplemented 10% fetal bovine serum (FCS). Cultures were maintained in a humidified atmosphere with 5% CO2 at 37˚C.

Chemicals and antibodies

Thiazolyl blue tetrazolium bromide (MTT), dimethysulfoxide (DMSO), prodidum iodide (PI) and Hoechst 33258 were bought from Sigma (Sigma-Aldrich, St. Louis, MO, USA). Polyclonal rabbit antibody against Cx43 and Cx32 were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA) and PTG (Chicago, IL, USA). γ-tubulin was bought from Jackson ImmunoResearch (Jackson, WY, USA).

Cell growth curve

The OCI-AML3 and OCIM2 cells were seeded in 24-well plates (2x104 per well), cultured in a humidified atmosphere with 5% CO2 at 37˚C. The cells were harvested and counted on days 1–4, three wells each time and three times each well, to obtain an average to draw the growth curve.

Cell proliferation assay

The proliferative rate of OCI-AML3 and OCIM2 was determined by MTT assay following the method of Mosmann (14). The OCI-AML3 and OCIM2 cells (1x104 per well) were cultured for 24, 48 and 72 h in 96-well plates. Thereafter, 20 μl MTT solution was added to each well. After continued incubation for 4 h, the supernatant was discarded and 150 μl DMSO was added. Once the blue crystals were dissolved, the optical density (OD) was measured at 490 nm with background substraction of 630 nm using a plate microreader (Tecan Spectra, Wetzlar, Germany). The experiments were performed in triplicate. The proliferation rate was determined using the following formula: Cell proliferation (%) = OD of the experimental samples / OD of the control x 100% (n=3, mean ± SD).

Cell cycle analysis

The OCI-AML3 and OCIM2 (1x106 cells) were harvested. After being washed, the cells were fixed with 75% ice-cold ethanol and maintained overnight at 4˚C. The cells were collected and resuspended in PBS containing 40 μg/ml PI, 0.1 mg/ml RNase, and 5% Triton X-100, and then incubated at 37˚C for 30 min. The cells were evaluated by flow cytometry (FCM) using FACS (BD, San Diego, CA, USA). At least 10,000 counts were made for each sample. The percentage distribution in the cell cycle phases was analyzed using CellQuest. The proliferation index (PI) was determined using the following formula: PI = (S + G2/M) / (G0/G1 + S + G2/M).

Semi-quantitative reverse transcription-PCR (RT-PCR)

Total RNA was extracted from OCI-AML3 and OCIM2 cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Following quantification by spectrophotometry, the first-strand cDNA was synthesized from 2 μg of total RNA with the RevertAid First-Strand cDNA Sythesis kit. Cx43: forward 5′-TCGCCTATGTCTCCTCCTGG-3′, reverse 5′-GCTGGCTCTGCTTGAAGGTC-3′, with a PCR product of 270 bp; Cx32: forward 5′-AAATGCTACGGCTTGA GGGC-3′, reverse 5′-CGGAACACCACGCTGATGAC-3′, which can amplify a 115 bp fragment; β-actin: forward 5′-G CG G GA A ATCGTG CGTGACAT TA-3′, reverse 5′-GACTCGTCATACTCCTGCTTGCTGAT-3′, with an expected PCR product of 480 bp. The products were electrophoresesed on 2% agarose gel and the ratio between the target gene and β-actin gene band density was used for quantitative evaluation.

Western blot analysis

For preparation of total cell lysates, cells were collected and lysed in lysis buffer (50 mM HEPES, 150 mM NaCl, 1% Triton X-100, 5 mM EGTA, 50 mM glycerophosphate, 20 mM NaF, 1 mM Na3VO4, 2 mM phenylmethyl sulfonyl fluoride, 10 μg/ml leupeptin and 10 μg/ml aprotinin) by incubating on ice for 30 min. Lysates were then centrifuged at 12,000 x g for 15 min at 4˚C. The supernatant was collected and the total protein concentrations were determined using the BCA assay by spectrophotometer (Biotech Instruments, NY, USA). Samples were separated on 10% SDS-PAGE and transferred onto nitrocellulose membranes. After blocking with 5% non-fat dry milk in blocking buffer (25 mM Tris, pH 7.5, 150 mM NaCl, and 0.1% Tween-20), the membranes were incubated with primary antibodies at 4˚C overnight. The membranes were then incubated with appropriate peroxidaseconjugated secondary antibodies, and the protein expression was detected by ECL substrate solution (Thermo Scientific, Rockford, IL, USA). Densitometric analysis was performed using Quantity One software.

Fluorescent immunostaining

OCI-AML3 and OCIM2 cells were collected and washed with PBS and then fixed with 40 mg/l paraformaldehyde for 10 min before deposition on polylysine-coated coverslips. After washing, samples were blocked with 10% goat serum albumin for 30 min. The cells were reacted overnight at 4˚C with a drop of 1:100 diluted Cx43 antibody, then washed and incubated with a drop of 1:500 diluted Cy3-labeled goat anti-rabbit IgG (Sigma, USA) for 1 h. After that, cells were stained with Hoechst 33258 for 30 min at 37˚C. Finally, the slides were mounted with 50% glycerol and observed by Olympus BH-2 fluorescence microscope (Tokyo, Japan).

Statistical analysis

The statistical significance of difference between control and treatment groups was determined by the Student’s t-test. Values are shown as the mean ± SD, and P<0.05 was considered to indicate a statistically significant difference.

Results

Growth curve and proliferation rate in AML cell lines OCI-AML3 and OCIM2

The OCI-AML3 and OCIM2 cells were seeded and cultured for 1–4 days, and cells were harvested and counted each day. According to the growth curve, as shown in Fig. 1A, the doubling time of OCI-AML3 and OCIM2 was 48 and 36 h respectively, and OCIM2 grew faster than OCI-AML3. To further confirm the proliferation rate of OCI-AML3 and OCIM2, the cells were seeded and cultured for 24, 48 and 72 h and detected by MTT. As shown in Fig. 2, the proliferation rate of OCIM2 was nearly twice that of OCI-AML3.

Figure 1

Assessment of proliferation rate of OCI-AML3 and OCIM2. (A) The OCI-AML3 and OCIM2 cells were seeded and cultured for 1, 2, 3 and 4 days. The cell number was counted each day. (B) The cells were seeded and cultured for 24 h, 48 h and 72 h. Viable cells were detected by MTT assay and the proliferation rate was calculated. The data shown is the mean ± SD from three independent experiments.

Figure 2

Assessment of cell cycle phase and proliferation index (PI) of OCI-AML3 and OCIM2. (A) The OCI-AML3 and OCIM2 cells were harvested and evaluated by flow cytometry using FACS. (B) The percentage distribution in the cell cycle phases was analyzed using CellQuest. The PI was determined using the following formula: PI = (S + G2/M) / (G0/G1 + S + G2/M). (C) S phase and PI are shown in histogram. Statistical significance was determined by the Student’s t-test. The data shown is the mean ± SD from three independent experiments. **P<0.01.

Cell cycle distribution and PI in AML cell lines OCI-AML3 and OCIM2

As shown in Fig. 2A, the cell cycle distribution of AML cell lines OCI-AML3 and OCIM2 was determined by FCM. As shown in Fig. 2B, the percentage of OCI-AML3 cells in the S phase fraction was 24.95±5.8%; however, the percentage of OCIM2 cells was much higher, at OCI-AML3, at 59.47±9.6%. At the same time, the PI of OCI-AML3 and OCIM2 was calculated to further confirm the role of the cell cycle in the proliferation rate of these two cell lines. As shown in Fig. 2B, that of OCIM2 was 78.12±8.9%, however, the PI of OCI-AML3 was only 35.21±6.7%. There were significant differences in S phase distribution and PI between OCI-AML3 and OCIM2, as shown in Fig. 2C (P<0.01).

Expression of Cx32, Cx43 mRNA and proteins in AML cell lines OCI-AML3 and OCIM2

To investigate whether there was a difference in the expression of Cxs in AML cell lines OCI-AML3 and OCIM2, the expression of Cx32, and Cx43 mRNA in OCI-AML3 and OCIM2 was detected by RT-PCR. The protein levels of Cx32 and Cx43 were determined by western blot assay and immunofluorescence. As shown in Fig. 3C and D, the RT-PCR assay showed that the expression of Cx43 and Cx32 mRNA in these two cell lines was not significantly different (P>0.05). In contrast, a clear difference was noted between OCI-AML3 and in OCIM2 in the expression of Cx43 protein. As shown in Fig. 3A and B, the protein level of Cx43 in OCIM2 was notably higher than that of OCI-AML3 (P<0.01).

Figure 3

The expression of Cx43 and Cx32 mRNA and protein in OCI-AML3 and OCIM2. (A) The OCI-AML3 and OCIM2 cells were harvested and the protein level of Cx43 and Cx32 was determined by western blot assay. (B) The values for Cx43 and Cx32 were corrected relative to γ-tubulin and are shown in the histogram. (C) The OCI-AML3 and OCIM2 cells were harvested and the mRNA levels of Cx43 and Cx32 were determined by RT-PCR. β-actin was used as an equal loading control. (D) The bands were quantified by densitometric analysis and are shown in the histogram. Statistical significance was determined by the Student’s t-test. The data is represented as the mean ± SD from three independent experiments. **P<0.01.

Cx43 proteins appeared as a collection of red spots intracytoplasmically and in certain parts of the plasma membrane, as shown in Fig. 4A. The immunofluorescence assay showed that the fluorescence intensity of Cx43 protein in OCIM2 was higher than that in OCI-AML3. OCIM2 cells showed both stronger western blot and fluorescence intensity. These results suggested that the expression of Cx43 in OCIM2 was much higher than OCI-AML3 at the protein level, but there was no difference at the mRNA level.

Figure 4

(A) The expression of Cx43 in OCI-AML3 and OCIM2 detected by immunofluorescence. The representative images are shown. (B) The intensity of Cx43 was quantitated by densitometric analysis and is shown in the histogram. Statistical significance was determined by the Student’s t-test. The data is represented as the mean ± SD from three independent experiments. **P<0.01.

Discussion

Deviation of physiological cell cycling, as a consequence of homeostatic imbalance, may lead to uncontrolled cell proliferation activity (15–17). The S phase (synthesis phase) is the part of the cell cycle in which DNA is replicated, occurring between the G1 and G2 phase, which is a reliable marker to indicate how fast a tumor is growing. In clinical practice, the S phase fraction could be used as an independent prognostic factor in node-negative invasive breast carcinoma (18). The proliferative index (PI) is a measure of the number of proliferated cells in a tumor, which is also an indicator of the cell proliferation rate. Our results revealed that OCIM2 grew much faster than OCI-AML3 and that the proliferation ability of OCIM2 was much stronger than that of OCI-AML3. In addition, the results showed that the S phase percentage and PI of OCIM2 was higher than OCI-AML3. Since acute erythroleukemia is an uncommon subtype of AML associated with a very poor prognosis compared to other subtypes, such as OCI-AML3, these results support the use of the S phase fraction as a parameter to predict the proliferation rate in AML cells.

It is well known that gap junctions, a group of specialized cell-to-cell junctions composed of Cx proteins (19–21), are critical gatekeepers of cell proliferation, controlling the intercellular exchange of essential growth regulators (22). The role of Cxs in leukemogenesis and leukemic cell functions are not well defined. Previous studies have clearly shown that soluble mediators alter AML cell proliferation and apoptosis both when the leukemic cells are cultured alone and when co-cultured with fibroblasts, endothelial cells and osteoblasts (23). Furthermore, direct cell-cell interactions between AML cells also alter AML cell function. Even though the function of Cx building blocks affects the regulation of several cellular functions, including growth and apoptosis of normal and malignant cells, and also appears to be important for chemosensitivity, little is known about their role in leukemic cell functions. Certain reports demonstrate that overexpression or genetic mutation of Cx could induce tumor cell growth and inhibit G1/S cell cycle arrest (12,24,25). In contrast, several studies have demonstrated that the presence of Cxs is indispensable for the enrollment of cell proliferation (26–29). Our research demonstrated a lower expression of Cx43 in OCI-AML3 than OCIM2, but RT-PCR results revealed no decrease of Cx43 mRNA in these two cell lines. It is of note, however, that the same level of Cx32 mRNA and proteins was detected in OCIM2 and OCI-AML3 cell lines. It appears that Cx43 gene transcription was not responsible for the aberrant expression of Cx43 proteins. Although there was no difference in the expression of Cx32 both at the transcriptional and protein level, we found that there was a significant difference in the expression of Cx43 at the protein level. Therefore, the results of the present study indicate that Cx43 could be considered as a potential tumor promoter which exerts its effect by promoting the exchange of growth factors or facilitating proliferation by itself as a pro-survival signal, and may also have a correlation with malignant AML cell proliferation. Further investigation is required to understand the precise mechanism in which intercellular communication participates in neoplastic growth in the hematopoietic process.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (no. 81070429).

Reference

1. 

M OyamadaY OyamadaT TakamatsuRegulation of connexin expressionBiochim Biophys Acta1719623200510.1016/j.bbamem.2005.11.00216359940

2. 

M KonoplevaS KonoplevW HuAY ZaritskeyBV AfanasievM AndreeffStromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteinsLeukemia1617131724200210.1038/sj.leu.240260812200686

3. 

DW LairdLife cycle of connexins in health and diseaseBiochem J394527543200610.1042/BJ2005192216492141

4. 

L CronierS CrespinPO StraleN DefamieM MesnilGap junctions and cancer: new functions for an old storyAntioxid Redox Signal11323338200910.1089/ars.2008.215318834328

5. 

M MesnilS CrespinJL AvanzoML Zaidan-DagliDefective gap junctional intercellular communication in the carcinogenic processBiochim Biophys Acta1719125145200510.1016/j.bbamem.2005.11.00416359943

6. 

SF GiardinaM MikamiF GoubaevaJ YangConnexin 43 confers resistance to hydrogen peroxide-mediated apoptosisBiochem Biophys Res Commun362747752200710.1016/j.bbrc.2007.08.06617761141

7. 

M FreidinS AscheTA BargielloMV BennettCK AbramsConnexin 32 increases the proliferative response of Schwann cells to neuregulin-1 (Nrg1)Proc Natl Acad Sci USA10635673572200910.1073/pnas.081341310619218461

8. 

X LiYB XuQ WangLeukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cellsJ Cell Physiol208594601200610.1002/jcp.2069516741927

9. 

Y LiuX ZhangZJ LiXH ChenUp-regulation of Cx43 expression and GJIC function in acute leukemia bone marrow stromal cells post-chemotherapyLeuk Res34631640201010.1016/j.leukres.2009.10.01319910046

10. 

Y LiuX ZhangYJ SiL GaoXH Chen[Connexin 43 expression and interacellular communicating function in acute leukemia bone marrow stroma cells]Zhongguo Shi Yan Xue Ye Xue Za Zhi156796822007

11. 

T KrenacsM RosendaalConnexin43 gap junctions in normal, regenerating, and cultured mouse bone marrow and in human leukemias: their possible involvement in blood formationAm J Pathol152993100419989546360

12. 

H SatoH HagiwaraY OhdeH SenbaN VirgonaT YanoRegulation of renal cell carcinoma cell proliferation, invasion and metastasis by connexin 32 geneJ Membr Biol2161721200710.1007/s00232-007-9020-517565422

13. 

Y HirabayashiBI YoonI TsuboiProtective role of connexin 32 in steady-state hematopoiesis, regeneration state, and leukemogenesisExp Biol Med (Maywood)232700712200717463168

14. 

DM SpinnerMTT growth assays in ovarian cancerMethods Mol Med39175177200121340769

15. 

M MalumbresM BarbacidCell cycle, CDKs and cancer: a changing paradigmNat Rev Cancer9153166200910.1038/nrc260219238148

16. 

R SuryadinataM SadowskiB SarcevicControl of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substratesBiosci Rep30243255201010.1042/BSR2009017120337599

17. 

S van den HeuvelCell-cycle regulationWormBook11620053318688

18. 

L Moureau-ZabottoC BouchetD CesariCombined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancerBreast Cancer Res Treat916171200510.1007/s10549-004-7047-1

19. 

M VinkenT VanhaeckeP PapeleuS SnykersT HenkensV RogiersConnexins and their channels in cell growth and cell deathCell Signal18592600200610.1016/j.cellsig.2005.08.01216183253

20. 

M VinkenT HenkensE De RopJ FraczekT VanhaeckeV RogiersBiology and pathobiology of gap junctional channels in hepatocytesHepatology4710771088200810.1002/hep.2204918058951

21. 

M VinkenE De RopE DecrockEpigenetic regulation of gap junctional intercellular communication: more than a way to keep cells quiet?Biochim Biophys Acta17955361200918801412

22. 

E DecrockM VinkenE De VuystConnexin-related signaling in cell death: to live or let die?Cell Death Differ16524536200910.1038/cdd.2008.19619197295

23. 

K HatfieldA RyningenM CorbascioO BruserudMicrovascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blastsInt J Cancer11923132321200610.1002/ijc.22180

24. 

C RogerB MograbiD ChevallierDisrupted traffic of connexin 43 in human testicular seminoma cells: overexpression of Cx43 induces membrane location and cell proliferation decreaseJ Pathol202241246200410.1002/path.1509

25. 

H SatoK FukumotoS HadaEnhancing effect of connexin 32 gene on vinorelbine-induced cytotoxicity in A549 lung adenocarcinoma cellsCancer Chemother Pharmacol60449457200710.1007/s00280-006-0406-317569045

26. 

CE ChadjichristosCM MatterI RothReduced connexin43 expression limits neointima formation after balloon distension injury in hypercholesterolemic miceCirculation11328352843200610.1161/CIRCULATIONAHA.106.62770316769907

27. 

H OzawaH MutaiT MatsunagaPromoted cell proliferation by connexin 30 gene transfection to head-and-neck cancer cell lineAnticancer Res2919811985200919528455

28. 

HH WangCI KungYY TsengActivation of endothelial cells to pathological status by down-regulation of connexin43Cardiovasc Res79509518200810.1093/cvr/cvn11218445604

29. 

X LiuT FuruyaD LiConnexin 26 expression correlates with less aggressive phenotype of intestinal type-gastric carcinomasInt J Mol Med25709716201020372813

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Yi S, Chen Y, Wen L, Yang L and Cui G: Expression of connexin 32 and connexin 43 in acute myeloid leukemia and their roles in proliferation. Oncol Lett 4: 1003-1007, 2012.
APA
Yi, S., Chen, Y., Wen, L., Yang, L., & Cui, G. (2012). Expression of connexin 32 and connexin 43 in acute myeloid leukemia and their roles in proliferation. Oncology Letters, 4, 1003-1007. https://doi.org/10.3892/ol.2012.884
MLA
Yi, S., Chen, Y., Wen, L., Yang, L., Cui, G."Expression of connexin 32 and connexin 43 in acute myeloid leukemia and their roles in proliferation". Oncology Letters 4.5 (2012): 1003-1007.
Chicago
Yi, S., Chen, Y., Wen, L., Yang, L., Cui, G."Expression of connexin 32 and connexin 43 in acute myeloid leukemia and their roles in proliferation". Oncology Letters 4, no. 5 (2012): 1003-1007. https://doi.org/10.3892/ol.2012.884
Copy and paste a formatted citation
x
Spandidos Publications style
Yi S, Chen Y, Wen L, Yang L and Cui G: Expression of connexin 32 and connexin 43 in acute myeloid leukemia and their roles in proliferation. Oncol Lett 4: 1003-1007, 2012.
APA
Yi, S., Chen, Y., Wen, L., Yang, L., & Cui, G. (2012). Expression of connexin 32 and connexin 43 in acute myeloid leukemia and their roles in proliferation. Oncology Letters, 4, 1003-1007. https://doi.org/10.3892/ol.2012.884
MLA
Yi, S., Chen, Y., Wen, L., Yang, L., Cui, G."Expression of connexin 32 and connexin 43 in acute myeloid leukemia and their roles in proliferation". Oncology Letters 4.5 (2012): 1003-1007.
Chicago
Yi, S., Chen, Y., Wen, L., Yang, L., Cui, G."Expression of connexin 32 and connexin 43 in acute myeloid leukemia and their roles in proliferation". Oncology Letters 4, no. 5 (2012): 1003-1007. https://doi.org/10.3892/ol.2012.884
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team